These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 1612008)

  • 21. Mullerian inhibiting substance: a gonadal hormone with multiple functions.
    Lee MM; Donahoe PK
    Endocr Rev; 1993 Apr; 14(2):152-64. PubMed ID: 8325249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mullerian inhibiting substance inhibits colony growth of a human ovarian carcinoma cell line.
    Fuller AF; Guy S; Budzik GP; Donahoe PK
    J Clin Endocrinol Metab; 1982 May; 54(5):1051-5. PubMed ID: 6895900
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclic adenosine 3',5'-monophosphate modulation of mullerian duct regression.
    Ikawa H; Hutson JM; Budzik GP; Donahoe PK
    Endocrinology; 1984 May; 114(5):1686-91. PubMed ID: 6201348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cellular localization of müllerian inhibiting substance in the developing rat ovary.
    Ueno S; Takahashi M; Manganaro TF; Ragin RC; Donahoe PK
    Endocrinology; 1989 Feb; 124(2):1000-6. PubMed ID: 2643506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cloning, expression, and alternative splicing of the receptor for anti-Müllerian hormone.
    di Clemente N; Wilson C; Faure E; Boussin L; Carmillo P; Tizard R; Picard JY; Vigier B; Josso N; Cate R
    Mol Endocrinol; 1994 Aug; 8(8):1006-20. PubMed ID: 7997230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human recombinant mullerian inhibiting substance inhibition of rat oocyte meiosis is reversed by epidermal growth factor in vitro.
    Ueno S; Manganaro TF; Donahoe PK
    Endocrinology; 1988 Sep; 123(3):1652-9. PubMed ID: 2456917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications.
    Donahoe PK; Clarke T; Teixeira J; Maheswaran S; MacLaughlin DT
    Mol Cell Endocrinol; 2003 Dec; 211(1-2):37-42. PubMed ID: 14656474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extended production of the müllerian duct regressor in the American alligator.
    Austin HB
    Gen Comp Endocrinol; 1994 Oct; 96(1):122-8. PubMed ID: 7843560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regression.
    Zhan Y; Fujino A; MacLaughlin DT; Manganaro TF; Szotek PP; Arango NA; Teixeira J; Donahoe PK
    Development; 2006 Jun; 133(12):2359-69. PubMed ID: 16687449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Steroid enhancement of Mullerian duct regression.
    Ikawa H; Hutson JM; Budzik GP; MacLaughlin DT; Donahoe PK
    J Pediatr Surg; 1982 Oct; 17(5):453-8. PubMed ID: 6897422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thyroid hormone and follicle-stimulating hormone regulate Müllerian-inhibiting substance messenger ribonucleic acid expression in cultured neonatal rat Sertoli cells.
    Arambepola NK; Bunick D; Cooke PS
    Endocrinology; 1998 Nov; 139(11):4489-95. PubMed ID: 9794457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytotoxic effects of müllerian inhibiting substance (MIS)?
    Janssens JP; Noto V; van Tendeloo G; Bonte J; de Loecker W
    Anticancer Res; 1988; 8(4):781-4. PubMed ID: 3178166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Müllerian inhibiting substance inhibits branching morphogenesis and induces apoptosis in fetal rat lung.
    Catlin EA; Tonnu VC; Ebb RG; Pacheco BA; Manganaro TF; Ezzell RM; Donahoe PK; Teixeira J
    Endocrinology; 1997 Feb; 138(2):790-6. PubMed ID: 9003016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant human mullerian inhibiting substance inhibits human ocular melanoma cell lines in vitro and in vivo.
    Parry RL; Chin TW; Epstein J; Hudson PL; Powell DM; Donahoe PK
    Cancer Res; 1992 Mar; 52(5):1182-6. PubMed ID: 1531323
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paracrine-mediated apoptosis in reproductive tract development.
    Roberts LM; Hirokawa Y; Nachtigal MW; Ingraham HA
    Dev Biol; 1999 Apr; 208(1):110-22. PubMed ID: 10075845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Müllerian-inhibiting substance: an update.
    Donahoe PK; Budzik GP; Trelstad R; Mudgett-Hunter M; Fuller A; Hutson JM; Ikawa H; Hayashi A; MacLaughlin D
    Recent Prog Horm Res; 1982; 38():279-330. PubMed ID: 6896925
    [No Abstract]   [Full Text] [Related]  

  • 37. Bioactivation of Müllerian inhibiting substance during gonadal development by a kex2/subtilisin-like endoprotease.
    Nachtigal MW; Ingraham HA
    Proc Natl Acad Sci U S A; 1996 Jul; 93(15):7711-6. PubMed ID: 8755541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mullerian inhibiting substance binding and uptake.
    Catlin EA; Ezzell RM; Donahoe PK; Manganaro TF; Ebb RG; MacLaughlin DT
    Dev Dyn; 1992 Apr; 193(4):295-9. PubMed ID: 1511169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Müllerian-inhibiting substance regulates androgen synthesis at the transcriptional level.
    Teixeira J; Fynn-Thompson E; Payne AH; Donahoe PK
    Endocrinology; 1999 Oct; 140(10):4732-8. PubMed ID: 10499532
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Highly purified müllerian inhibiting substance inhibits human ovarian cancer in vivo.
    Stephen AE; Pearsall LA; Christian BP; Donahoe PK; Vacanti JP; MacLaughlin DT
    Clin Cancer Res; 2002 Aug; 8(8):2640-6. PubMed ID: 12171896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.